4 OCT
Vision Stage
Bettina van Wylich-Muxoll
Managing Partner
Bettina van Wylich-Muxoll is an international healthcare executive and entrepreneur with more than 15 years of experience spanning precision medicine, digital health, diagnostics, preventive healthcare and commercialisation. She is Co-Founder and Managing Partner of BioAgeDiagnostics, a European longevity healthcare company focused on translating advances in biological ageing and precision diagnostics into clinically relevant and commercially scalable solutions. BioAgeDiagnostics works with healthcare providers and diagnostic innovators to advance personalised prevention and healthy longevity.
Linkedin: https://www.linkedin.com/in/bettinavanwylich/ Website: https://www.bioagediagnostics.com/
ABOUT THE SESSION
From Measuring Biological Age to Reversing It – The Next Frontier in Longevity Medicine
4 OCT · Vision Stage · 15:10
Dozens of biological age clocks are now on the market, and biological age has become a popular biomarker in its own right. Yet one question often goes unanswered: what can a person actually do with the result? There is still little data on actionability, meaning whether a clock responds to concrete interventions and reliably reflects changes in health status over time. This gap matters most in longevity medicine, a field full of promises but short on clinical evidence. To separate effective interventions from hype, we need health and performance biomarkers that can validate them longitudinally.
This talk presents a proteomics-based approach to closing that gap. A proteomic clock, built from LC-MS analysis of a simple buccal swab, provides more than a single biological age estimate. It also generates sub-markers for the underlying cellular processes. This added resolution turns an abstract number into specific feedback on which biological systems are changing.